Pharming sees FY26 revenue $405M-$425M, consensus $411.9M

Sees FY26 operating expenses $330M-$335M. The company said, “Finally, our focus on financial discipline also delivered tangible results, including positive net cash flow from operations in the quarter despite quarterly revenue variability. Taken together, our commercial execution, regulatory progress, pipeline advancement, and disciplined financial management position Pharming (PHAR) well for sustained long-term growth and value creation.”